With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about ...
Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...
Elranatamab-bcmm (Elrexfio) demonstrated poorer progression-free survival (PFS) but greater response rates vs eclistamab-cqyv (Tecvayli) in patients with relapsed/refractory multiple myeloma according ...
Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a ...
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single ...
Tocilizumab has been used since the early 2010s for conditions such as rheumatoid arthritis, giant cell arteritis, and others ...
Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...
Sequential ICV and IV administration of CR7-GD2 CAR T-cell therapy showed improved tolerability over concurrent dosing in ...
Celltrion is offering Avtozma (tocilizumab-anoh) intravenous formulation, which is a biosimilar of Chugai Pharmaceutical’s Actemra. Avtozma is used to treat rheumatoid arthritis, giant cell arteritis, ...
INCHEON, South Korea, Oct. 2, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA ® (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback